Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825616 | 0.94 | PRMT5 (0.80) | PRMT5WDR77 | |
| SCHEMBL16220706 | 0.94 | PRMT5 (0.80) | PRMT5WDR77 | |
| SCHEMBL32617545 | 0.94 | PRMT5 (0.80) | PRMT5WDR77 | |
| SCHEMBL15944604 | 0.89 | PRMT5 (0.64) | PRMT5WDR77 | |
| SCHEMBL21140499 | 0.89 | PRMT5 (0.81) | PRMT5WDR77 | |
| SCHEMBL16220899 | 0.89 | PRMT5 (0.81) | PRMT5WDR77 | |
| SCHEMBL15944662 | 0.88 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15944634 | 0.88 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15819867 | 0.88 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15944657 | 0.86 | PRMT5 (0.71) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20140228360-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228360-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 74/4885 |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.